Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Efficacy of Cholesterol-lowering L. Plantarum on Cardiometabolic Health Biomarkers in Coeliac Disease Patients

A legfontosabb adatok

Ki végzi
University of Roehampton
Hol
Egyesült Királyság és Olaszország2 helyszín, 2 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
50 fő vett részt
Kezdés
2022. ápr. 12.
Befejezés
2025. dec. 21.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • LP-LDL Probiotic
  • Placebo Comparator
A regiszteradat frissítve
2026. május 11.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults aged between 18 and 65 years, with CD Diagnosis
  • Fasting blood glucose level not above 5.6-6.9mmol/L
  • High baseline cholesterol (TC> 6mmol / L)
  • HbA1c below 5.7%
  • With cholesterol
  • For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English

Ki nem vehet részt

  • People receiving drug treatment for lipid metabolisms (e.g., statins
  • People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, uncontrolled hypertension, cancer or major psychiatric or cognitive problems
  • People with a history of long-term use of medicines known to influence glucose metabolism (e.g., corticosteroids)
  • People who are already participating in a weight loss programme
  • People with elevated liver enzymes (alanine aminotransferase ≥300 IU/L, aspartate aminotransferase ≥300 IU/L)
  • People who take antibiotics or bacterial agents (Probiotics) within 1 month
  • Pregnant women, women ready for pregnancy, and nursing mothers; All capsules (probiotic and placebo) have the same taste and appearance and have been mixed, encapsulated and packaged to ensure product consistency throughout the study. All capsules will be distributed free of charge to participants in this study

Hol van ez a vizsgálat?

2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Recent studies have also shown that 30% of the world's population carries the susceptibility genes for coeliac disease and that only 2-5% of these individuals are really affected, however, studies suggest the existence of other factors capable of contributing to the onset of the disease, such as intestinal dysbiosis. We have also seen how each of us has a specific microbiota, defined as an individual human enterotype, which depends on our background and can be modified by the diet. Recently, much interest has been directed to a strain of lactobacilli, called Lactobacillus plantarum (LP-LDL®) capable of reducing cholesterol and preventing the reabsorption of bile salts in the liver. The efficacy of this bacterial strain has been confirmed in 3 different human studies demonstrating the efficacy of LP-LDL® in patients with high baseline cholesterol (TC> 6mmol / L). This is a food supplement that has been commercially available in multiple formulations in Europe for over 3 years. LP-LDP is a probiotic strain, safe to use, selected for its high bile salt hydrolase in vitro, and in vivo cholesterol reduction activity. The intake of 2 Å~ 109 CFU encapsulated LP-LDL twice daily, significantly reduced LDL-C (13.9%), total cholesterol (TC) (37.6%), TG (53.9%), and significantly increased HDL-C (14.7%; in subjects >60 years of age; 6-12 weeks) in normal to mildly hypercholesterolaemic subjects. In a recent double-blind placebo-controlled human study published by the Journal of Functional Foods (2022) and carried out by the University of Roehampton (UK), LPLDL showcased statistically significant reductions in multiple cardiovascular risk biomarkers, including total cholesterol, LDL cholesterol, non-HDL cholesterol and apoB. No adverse effects were noted throughout the study.

A teljes eredeti leírásKevesebb

We are here proposing a pilot human intervention study to evaluate the effectiveness of the LP-LDL® probiotic in reducing cardiovascular risk factors inclusive of cholesterol in the blood in people with coeliac disease.

A vizsgálat 2 csoportja

  • ProbioticA vizsgált kezelés

    Lactobacillus plantarum (LPLDL®) equivalent to 4 x10\^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.

    Kezelés: LP-LDL Probiotic

  • placeboPlacebo, összehasonlításként

    Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.

    Kezelés: Placebo Comparator

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
UOC DI GASTROENTEROLOGIA AOU S.GIOVANNI DI DIO E RUGGI D'ARAGONA (Italy) & University of Roehampton (UK)
A regiszteradat frissítve
2026. május 11.